Peer-Reviewed Publication
JCI Insight2026;11(4)February 23, 2026Journal Article
Dose-dependent IFN programs in myeloid cells after mRNA and adenovirus COVID-19 vaccination.
Giray Eryilmaz1, Yilmaz Yucehan Yazici1, Radu Marches1, Eleni P Mimitou2, Lisa Kenyon-Pesce3, Kim Handrejk4,5, Sonia Jangra4,5, Michael Schotsaert4,5,6,7, Adolfo García-Sastre4,5,7,8,9,10, George A Kuchel3, Jacques Banchereau1,11, Duygu Ucar1,12
1The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA.
2Immunai, New York, New York, USA.
3UConn Center on Aging, UConn Health, Farmington, Connecticut, USA.
4Department of Microbiology.
5Global Health and Emerging Pathogens Institute.
6Marc and Jennifer Lipschultz Precision Immunology Institute.
7Icahn Genomics Institute.
8Department of Medicine, Division of Infectious Diseases.
9The Tisch Cancer Center, and.
10Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
11Immunoledge LLC, Montclair, New Jersey, USA.
12Department of Genetics and Genome Sciences, University of Connecticut Health Center, Farmington, Connecticut, USA.
Abstract
BACKGROUNDThe SARS-CoV-2 pandemic provided a rare opportunity to study how human immune responses develop to a novel viral antigen delivered through different vaccine platforms. However, to date, no study has directly compared immune responses to all 3 FDA-approved COVID-19 vaccines at single-cell multiomic resolution.METHODSWe longitudinally profiled SARS-CoV-2-naive adults (n = 31) vaccinated wi…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans